Why It Matters

Paytient Technologies is lobbying amid a healthcare affordability crisis forcing millions of Americans to delay or skip care due to cost. With enhanced ACA subsidies expiring this year and marketplace premiums rising sharply, more consumers face larger out-of-pocket expenses. This is problem Paytient’s Health Payment Account is designed to solve. The company is targeting the Medicare Prescription Payment Plan and broader ACA affordability policies, betting that the Trump administration’s emphasis on consumer-directed healthcare and new price transparency mandates will drive demand for its financing platform.

By the Numbers

Paytient Technologies Inc. spent $50,000 in first quarter 2026 with Bockorny Group Inc., continuing a relationship central to its federal advocacy since January 2024. The company has invested $785,230 total across 20 disclosures over roughly two years.

Paytient relies on two firms: Bockorny Group has handled $555,000 across 11 disclosures, supplemented by DeBrunner & Associates Inc. at $230,230 through early 2026. Prior disclosures list Eric Edmund Bohl from Bockorny as the primary contact.

Bockorny’s roster includes the American Hospital Association, CVS Health, and Sanford Health, giving Paytient access to a firm with dual expertise in healthcare and finance—valuable for a fintech operating at their intersection.

The Agenda

Healthcare fintech Paytient Technologies Inc. is lobbying on healthcare payment innovation and affordability—specifically targeting the Medicare Prescription Payment Plan and policies around smoothing out-of-pocket costs for consumers.

Paytient offers a sponsored line of credit allowing employees to finance healthcare expenses through interest-free repayment plans. The company testified before Congress in December 2025 on technology’s role in driving healthcare affordability, underscoring its strategy to influence implementation of new government payment programs. Relevant legislation includes bills on price transparency and Health Savings Account expansion—both creating demand for financing tools like Paytient’s.

Broader Context

The immediate catalyst is expiring enhanced ACA subsidies, pushing marketplace premiums up by as much as 59 percent in some regions for 2026. Trump’s \"Great Healthcare Plan\" prioritizes price transparency and expanded HSAs—both driving demand for payment financing tools. Nearly half of American adults struggle to afford healthcare, one-third skip needed care due to cost, and roughly 41 percent carry medical debt.

Between The Lines

In December 2025, Brian Whorley of Paytient testified before the House Oversight Subcommittee on technology’s role in driving affordability. Advancing legislation includes the Patients Deserve Price Tags Act, the Health Care PRICE Transparency Act, and the Healthcare Freedom Act. Sen. Tim Scott and others are actively advocating for innovative payment models.

Competitive Landscape

Paytient operates in a crowded space. Claritev Corp. spent $320,000 in 2025 lobbying on healthcare payment services, while major players are investing heavily:

The Bottom Line

Paytient Technologies spent $50,000 in the first quarter 2026 lobbying through Bockorny Group, sustaining a campaign focused on healthcare affordability policy. With ACA subsidies expiring and the Trump administration pushing consumer-directed healthcare, Paytient is positioning its fintech model as a practical policy solution—while competing against well-resourced incumbents for federal influence.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article